PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34735897-7 2022 Pictilisib treatment inhibited the protein kinase B (AKT) cell survival pathway and promoted a pro-apoptotic phenotype as evidenced by quantitative real time polymerase chain reaction (qRT-PCR) analysis of the B-cell lymphoma 2 (BCL2) protein family members (P<0.01). 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0-10 AKT serine/threonine kinase 1 Homo sapiens 53-56 33659212-0 2020 Pictilisib Enhances the Antitumor Effect of Doxorubicin and Prevents Tumor-Mediated Bone Destruction by Blockade of PI3K/AKT Pathway. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0-10 AKT serine/threonine kinase 1 Homo sapiens 121-124 33659212-11 2020 Pictilisib combined with conventional chemotherapy drugs represents a potential treatment strategy to suppress tumor growth and bone destruction in p-AKT-positive patients. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 0-10 AKT serine/threonine kinase 1 Homo sapiens 150-153 28536078-8 2017 Moreover, we found that sorafenib reversed dabrafenib inhibition of AKT in HT-29 cells, and phosphatidylinositol-3-kinase (PI3K) inhibitor GDC0941 significantly restored this antagonistic effect when combined with dabrafenib and sorafenib, indicating that AKT is critically involved in this antagonism. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 139-146 AKT serine/threonine kinase 1 Homo sapiens 256-259 32514232-7 2020 After docking and several comparisons, inhibitors with better predictions showed better affinity and interaction with PI3K compared to pictilisib and dactolisib, so we found that 4 inhibitors of AKT and 14 mTOR inhibitors met the criteria of Lipinski and Veber and could be future drugs. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 135-145 AKT serine/threonine kinase 1 Homo sapiens 195-198 31553879-5 2019 We designed a new 18F-radiolabeled radiotracer based on the structure of pictilisib, to evaluate noninvasively abnormal activation of the PI3K/AKT/mTOR pathway. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 73-83 AKT serine/threonine kinase 1 Homo sapiens 143-146 28291364-0 2017 Multifunctional Nanoparticles Loading with Docetaxel and GDC0941 for Reversing Multidrug Resistance Mediated by PI3K/Akt Signal Pathway. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 57-64 AKT serine/threonine kinase 1 Homo sapiens 117-120 28029662-12 2017 By screening a set of compounds that are associated with the genetic alteration, it has been found that GDC-0941 and PF-04691502 for PI3K-AKT-mTOR pathway inhibitors could dramatically decrease the proliferation of three patient-derived cells. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 104-112 AKT serine/threonine kinase 1 Homo sapiens 138-141 28029662-13 2017 Importantly, expression of phosphorylated AKT and phosphorylated S6 were markedly decreased after treatments with PI3K-AKT-mTOR pathway inhibitors GDC-0941 (0.5 muM) and PF-04691502 (0.1 muM) in all three patient-derived cells. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 147-155 AKT serine/threonine kinase 1 Homo sapiens 42-45 28029662-13 2017 Importantly, expression of phosphorylated AKT and phosphorylated S6 were markedly decreased after treatments with PI3K-AKT-mTOR pathway inhibitors GDC-0941 (0.5 muM) and PF-04691502 (0.1 muM) in all three patient-derived cells. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 147-155 AKT serine/threonine kinase 1 Homo sapiens 119-122 27465249-9 2016 Furthermore, downstream PI3K pathway alterations in TSC1 or PTEN or co-occurring AKT1 and RAS gene mutations were associated with GDC-0941 resistance. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 130-138 AKT serine/threonine kinase 1 Homo sapiens 81-85 25370471-7 2015 Levels of phosphorylated serine-473 AKT were suppressed >90% in PRP at 3 hours after dose at the MTD and in tumor at pictilisib doses associated with AUC >20 h mumol/L. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 120-130 AKT serine/threonine kinase 1 Homo sapiens 36-39 25941816-6 2015 Furthermore, we found that EA promoted apoptosis and further reduced AKT/mTOR activation in GDC-0941- treated breast cancer cells. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 92-100 AKT serine/threonine kinase 1 Homo sapiens 69-72 23602735-7 2013 AZD6244 abrogated p-ERK and GDC0941 abrogated p-AKT levels, confirming their expected target effects. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 28-35 AKT serine/threonine kinase 1 Homo sapiens 48-51 24601221-8 2014 In addition, GDC-0941 resulted in decreased Akt activity. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 13-21 AKT serine/threonine kinase 1 Homo sapiens 44-47 23711387-8 2013 Treatment with AKT inhibitor GDC0941 dramatically reversed the effects of Erbin knockdown on the cell migration and trastuzumab resistance, which is mainly mediated by aberrant activation of AKT. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 29-36 AKT serine/threonine kinase 1 Homo sapiens 15-18 23711387-8 2013 Treatment with AKT inhibitor GDC0941 dramatically reversed the effects of Erbin knockdown on the cell migration and trastuzumab resistance, which is mainly mediated by aberrant activation of AKT. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 29-36 AKT serine/threonine kinase 1 Homo sapiens 191-194 23602735-11 2013 CONCLUSION: Concomitant suppression of MEK/ERK and PI3K/AKT pathways by AZD6244 and GDC0941 abrogates compensatory mechanisms of tumor survival and causes synergistic cytotoxicity in thyroid cancer cells. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 84-91 AKT serine/threonine kinase 1 Homo sapiens 56-59 23006739-6 2012 In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 13-21 AKT serine/threonine kinase 1 Homo sapiens 51-54 23006739-6 2012 In addition, GDC-0941 blocked the feedback of PI3K/Akt through S6K1, resulting in decreased Akt activity by rapamycin activation. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 13-21 AKT serine/threonine kinase 1 Homo sapiens 92-95 20826841-7 2010 This increased phospho-Akt(Ser473) response to doxorubicin correlates with the strength of GDC-0941"s effect to augment doxorubicin action. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 91-99 AKT serine/threonine kinase 1 Homo sapiens 23-26 21994956-13 2011 In vivo, GDC-0941 reduced expression of HIF-1alpha, phospho-AKT, GLUT-1, and lactate dehydrogenase A in FTC xenografts. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 9-17 AKT serine/threonine kinase 1 Homo sapiens 60-63 20361045-8 2010 The PDK1-IFPC::IFPN-AKT1 complex was sufficient for phosphorylation of known AKT substrates, and conferred resistance to inhibitors of PI3K (LY294002, PI103, GDC0941 and TGX286) but not inhibitors of the downstream TORC1 complex (rapamycin). 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 158-165 AKT serine/threonine kinase 1 Homo sapiens 20-24 20361045-8 2010 The PDK1-IFPC::IFPN-AKT1 complex was sufficient for phosphorylation of known AKT substrates, and conferred resistance to inhibitors of PI3K (LY294002, PI103, GDC0941 and TGX286) but not inhibitors of the downstream TORC1 complex (rapamycin). 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 158-165 AKT serine/threonine kinase 1 Homo sapiens 20-23 19382889-8 2009 The AKT inhibitor triciribine and the PI3K inhibitor GDC-0941 also resulted in the enhanced reporter activity, strongly implicating a role for the PI3K/AKT pathway in regulating NICD signaling. 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine 53-61 AKT serine/threonine kinase 1 Homo sapiens 152-155 23300603-8 2012 However, this reduction was greatly ameliorated in the presence of octreotide at 24 h and 48 h. The protein expression of CHAT neurons at 24 h and the nNOS neurons at 48 h in the ANP+octreotide rats was much higher than the ANP+saline rats. Octreotide 183-193 nitric oxide synthase 1 Rattus norvegicus 151-155 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 annexin A1 Homo sapiens 74-84 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 annexin A1 Homo sapiens 86-91 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 Rho GTPase activating protein 18 Homo sapiens 94-126 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 Rho GTPase activating protein 18 Homo sapiens 128-136 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 epithelial membrane protein 1 Homo sapiens 139-168 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 epithelial membrane protein 1 Homo sapiens 170-174 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 growth differentiation factor 15 Homo sapiens 177-209 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 growth differentiation factor 15 Homo sapiens 211-216 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 transforming growth factor beta receptor 2 Homo sapiens 219-244 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 transforming growth factor beta receptor 2 Homo sapiens 246-252 23119007-10 2012 Unexpectedly, six novel genes were found to be upregulated by octreotide: annexin A1 (ANXA1), rho GTPase-activating protein 18 (ARHGAP18), epithelial membrane protein 1 (EMP1), growth/differentiation factor 15 (GDF15), TGF-beta type II receptor (TGFBR2) and tumour necrosis factor (ligand) superfamily member 15 (TNFSF15). Octreotide 62-72 TNF superfamily member 15 Homo sapiens 313-320 22574156-1 2012 BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage. Octreotide 50-60 growth hormone 1 Homo sapiens 119-133 22574156-1 2012 BACKGROUND: The long-acting somatostatin analogue octreotide is used either as an adjuvant or primary therapy to lower growth hormone (GH) levels in patients with acromegaly and may also induce pituitary tumor shrinkage. Octreotide 50-60 growth hormone 1 Homo sapiens 135-137 22574156-11 2012 In patients treated with the LAR formulation of octreotide, this increased to 66.0%, [95% CI: 57.0%-74.0%). Octreotide 48-58 protein tyrosine phosphatase receptor type F Homo sapiens 29-32 22509294-6 2012 As a whole, these data indicate the relevant role played by somatostatin and, potentially, by analogue octreotide, in preventing Abeta accumulation by partially restoring IDE activity. Octreotide 103-113 amyloid beta precursor protein Homo sapiens 129-134 22509294-6 2012 As a whole, these data indicate the relevant role played by somatostatin and, potentially, by analogue octreotide, in preventing Abeta accumulation by partially restoring IDE activity. Octreotide 103-113 insulin degrading enzyme Homo sapiens 171-174 22110271-0 2011 Effects of octreotide on glucose transporter type 2 expression in obese rat small intestine. Octreotide 11-21 solute carrier family 2 member 2 Rattus norvegicus 25-51 22977639-9 2011 It is suggested that OCT inhibits ovarian cancer proliferation and promotes apoptosis, via the cell surface expression of SSRT2, and reverses cisplatin resistance through the inhibition of MRP2 and EGFR expression. Octreotide 21-24 ATP binding cassette subfamily C member 2 Homo sapiens 189-193 22977639-9 2011 It is suggested that OCT inhibits ovarian cancer proliferation and promotes apoptosis, via the cell surface expression of SSRT2, and reverses cisplatin resistance through the inhibition of MRP2 and EGFR expression. Octreotide 21-24 epidermal growth factor receptor Homo sapiens 198-202 22052632-0 2011 Epileptic seizures after octreotide administration in a 6.5-year-old female with ALL and L-asparaginase associated pancreatitis: a possible drug interaction. Octreotide 25-35 asparaginase and isoaspartyl peptidase 1 Homo sapiens 89-103 22052632-2 2011 CASE REPORT: we present a rare case of a 6.5-year-old female with acute lymphoblastic leukemia (ALL) and L-asparaginase (L-asp) induced pancreatitis, who developed epileptic seizures, possibly associated with octreotide administration. Octreotide 209-219 asparaginase and isoaspartyl peptidase 1 Homo sapiens 105-119 22052632-2 2011 CASE REPORT: we present a rare case of a 6.5-year-old female with acute lymphoblastic leukemia (ALL) and L-asparaginase (L-asp) induced pancreatitis, who developed epileptic seizures, possibly associated with octreotide administration. Octreotide 209-219 asparaginase and isoaspartyl peptidase 1 Homo sapiens 105-110 21978505-1 2011 BACKGROUND: Octreotide is a synthetic octapeptide having properties related to those of natural somatostatin, a hypothalamic hormone. Octreotide 12-22 somatostatin Homo sapiens 96-108 21911723-0 2011 Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. Octreotide 60-70 protein tyrosine phosphatase receptor type F Homo sapiens 71-74